![](/img/cover-not-exists.png)
Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
Moetaza M. Soliman, Kimme L. Hyrich, Mark Lunt, Kath D. Watson, Deborah P. M. Symmons, Darren M. Ashcroft, on behalf of the British Society for Rheumatology Biologics RegisterVolume:
64
Year:
2012
Language:
english
Pages:
1
DOI:
10.1002/acr.21663
File:
PDF, 142 KB
english, 2012